Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Researchers develop living 3D lab model of human retina
➤ Real-world data shows home AMD monitoring program is better than standard of care
➤ FDA approves new ophthalmic viscosurgical device
➤ Positive topline data for photobiomodulation for dry AMD
➤ Positive topline data for bevacizumab-vikg for retinal indications
➤ FDA approves enhanced monovision IOL
➤ Report: Demand for refractive surgery up amid pandemic
➤ Study: Antifibrotic activity of rho-kinase inhibitors
➤ Companies partner to explore nanoparticle applications for ophthalmic therapies
➤ ASCRS Journal Club on April 8
➤ Phase 2 clinical trial of minocycline for MGD
➤ Phase 2a study of drug-eluting contact lens for glaucoma
➤ Phase 1/2 results of RNA therapy for Usher syndrome, non-syndromic retinitis pigmentosa
➤ First regulatory approval for a therapeutic contact lens that treats ocular allergies
➤ Moist heat masks effective for signs, symptoms of dry eye, study finds
➤ ASCRS Journal Club on April 8
➤ FDA accepts IND for presbyopia-correcting eye drop
➤ Pivotal study of new tech against gold standard patching treatment of amblyopia
➤ Topline results from trial to reverse pharmacologically induced mydriasis
➤ Pivotal study of fixed-combination tropicamide/phenylephrine product for mydriasis
➤ ASCRS introduces new Richard L. Lindstrom Lecture
➤ FDA approves elements of artificial vision system for blind patients
➤ Expanded indication for MIGS device
➤ 5-year pivotal trial data for MIGS device
➤ Topline results from Phase 2 study of investigational MGD treatment
➤ FDA accepts NDA for fixed-combination mydriatic agent
➤ NDA accepted by FDA for dry eye nasal spray
➤ NDA submitted for drop to treat presbyopia
➤ Study to assess outcomes of ab interno canaloplasty
➤ Largest study of glaucoma genetics published
➤ Iridex and Topcon enter into strategic agreement
➤ COVID-19 vaccine update
➤ ASCRS Journal Club on March 11
➤ PMA submitted to FDA for small-aperture IOL
➤ Preclinical results for new class of non-prostaglandin analogs for IOP lowering
➤ A Phase 2 clinical trial begins enrollment for topical presbyopia-correcting drop
➤ Home OCT technology used in clinical trial to reduce participant visits to offices
➤ ASCRS Journal Club on March 11
➤ Investigating adjuvant therapy to DSO for Fuchs
➤ FDA approves loteprednol etabonate ophthalmic gel
➤ Pilot study: Photobiomodulation improves BCVA in patients with dry AMD
➤ Positive interim data in trial for gene therapy for GA
➤ Four Phase 3 studies of faricimab show up to 4-month treatment intervals for DME and wet AMD
➤ NDA filed for topical glaucoma and ocular hypertension ophthalmic solution
➤ Nepafenac vs. placebo, results from Phase 2 study
➤ Enrollment completed for photobiomodulation treatment trial
➤ ASCRS activity updates
➤ 2021 ASCRS Annual Meeting update
➤ FDA approves new monofocal IOL
➤ First patient dosed in Phase 2 trial for investigational DED therapy
➤ Phase 2a trial initiated for add-on wet AMD therapy